and @edgck, If I can male a suggestion, review all of VRS37 posts carefully. This person is an ill informed person who just posts stuff with no clinical correlation
1) Rituximab as a drug has been used in most of these rare conditions when standard lines of treatment have failed or show no improvement. If you do a quick search on pubmed for rituximab in FSGS you will see that there are calls for a randomised controlled study (of which none have been done yet that I am aware of, happy to be corrected). So as such, clinicians are using it in cases to either buy time prior to a transplant or using it in post transplant patients.
2) From the above statement, what DXB are trying to achieve is a first of its kind in the treatment for FSGS. Once this commercialises, it would have been a drug that has been studied in all phase trials and shown to have a beneficial effect, unlike rituximab which has no randomised trials.
if rituximab is a cheaper option, its only observational. There would have to be a proper study done to compare the DXB with Rituximab to show that efficacy is same/better/worse from a price perspective.
So from the box that VRS37 put up, it is only a matter of time before that flowchart is revised once Dimerix hits the market.
DYOR
- Forums
- ASX - By Stock
- DXB
- Ann: Investor Presentation
Ann: Investor Presentation, page-103
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
53.0¢ |
Change
0.020(3.92%) |
Mkt cap ! $291.6M |
Open | High | Low | Value | Volume |
51.0¢ | 53.8¢ | 51.0¢ | $782.0K | 1.490M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6408 | 53.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
53.5¢ | 35657 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6408 | 0.530 |
2 | 48000 | 0.525 |
6 | 113118 | 0.520 |
4 | 57872 | 0.515 |
14 | 177420 | 0.510 |
Price($) | Vol. | No. |
---|---|---|
0.535 | 35657 | 1 |
0.540 | 75830 | 5 |
0.545 | 232172 | 7 |
0.550 | 73893 | 6 |
0.555 | 120000 | 2 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online